| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(4 years from now) | |
Keppra Xr is owned by Ucb Inc.
Keppra Xr contains Levetiracetam.
Keppra Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Keppra Xr was authorised for market use on 12 September, 2008.
Keppra Xr is available in tablet, extended release;oral dosage forms.
The generics of Keppra Xr are possible to be released after 17 September, 2028.
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of KEPPRA XR before it's drug patent expiration?
More Information on Dosage
KEPPRA XR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic